UCB’s Bimekizumab Gets Fast-Track Funding For Severe Psoriasis In England
New HTA Route For “Low-Risk” Products Offers Rapid Patient Access
It may not yet be approved for marketing, but UCB’s potential blockbuster psoriasis drug has already got the all-clear from NICE, the health technology body that appraises new products for use in England and Wales.
You may also be interested in...
Big Year For UCB As Bimzelx Awaits US Green Light
The Brussels-based company's head of immunology has told Scrip that going into a crowded market against several highly effective biologics across different classes holds no fears for UCB despite some concerns that US prescribers will stick to what they know when it comes to psoriasis therapies.
Scotland's HTA Body Says Fast-Track Yes To UCB’s Bimzelx
The Scottish health technology appraisal body also OKd Janssen's Ponvory and new indications for AstraZeneca’s Tagrisso, Roche’s Tecentriq and MSD’s Keytruda. It also said it could not make recommendations on a number of drugs because manufacturers had not made a submission to the SMC.
Potential 'Mega-Blockbuster' Bimzelx Heading For Psoriasis Market In UK & EU
Bimzelx, which is expected to make a big splash in the psoriasis market, received its two marketing authorizations just days apart.